

Dated: May 18, 2007.

Susan K. Fawcett,
Records Officer, U.S. Patent and Trademark
Office, Office of the Chief Information Officer,
Customer Information Services Group, Public
Information Services Division.

[FR Doc. E7-10042 Filed 5-23-07; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF COMMERCE

Patent and Trademark Office

[Docket No. PTO-P-2007-0021]

Grant of Interim Extension of the Term of U.S. Patent No. 4,927,855; NUVIGILTM (armodafinil)

AGENCY: United States Patent and
Trademark Office, Commerce.

ACTION: Notice of interim patent term
extension.

SUMMARY: The United States Patent and
Trademark Office has issued an order
granting interim extension under 35
U.S.C. 156(d)(5) for a one-year interim
extension of the term of U.S. Patent No.
4,927,855.

FOR FURTHER INFORMATION CONTACT:

Mary C. Till by telephone at (571) 272-
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Hatch-Waxman PTE.,
P.O. Box 1450, Alexandria, VA 22313-
1450; by fax marked to her attention at
(571) 273-7755, or by e-mail to
Mary.Till@uspto.gov.

SUPPLEMENTARY INFORMATION: Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.

On May 7, 2007, Cephalon, Inc., an
agent of Laboratoire L. Lafon, the owner
of record in the United States Patent and
Trademark Office of U.S. Patent No.
4,927,855, timely filed an application
under 35 U.S.C. 156(d)(5) for an interim
extension of the term of U.S. Patent No.
4,927,855. The patent claims the human
drug product NUVIGILTM (armodafinil)
and a method of said product. The
application indicates, and the Food and
Drug Administration has confirmed,
that a new drug application (NDA 21-
875) for the human drug product
NUVIGILTM (armodafinil) has been
filed and is currently undergoing
regulatory review before the Food and

Drug Administration for permission to
market or use the product commercially.

Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the original
expiration date of the patent (May 22,
2007), interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.

An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,927,855 is granted for a period of one
year from the expiration date of the
patent, i.e., until May 22, 2008.

Dated: May 18, 2007.

Jon W. Dudas,

Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.

[FR Doc. E7-10084 Filed 5-23-07; 8:45 am]

BILLING CODE 3510-16-P

DEPARTMENT OF DEFENSE

Office of the Secretary

Sub Committee Meeting of the President's Commission on Care for America's Returning Wounded Warriors

AGENCY: Department of Defense.

ACTION: Federal Advisory Committee
Sub Committee Meeting Notice.

SUMMARY: Pursuant to the Federal
Advisory Committee Act of 1972 (5
U.S.C., Appendix, as amended), the
Sunshine in the Government Act of
1976 (5 U.S.C. 552b, as amended) and
41 Code of Federal Regulations (CFR)
102-3.140 thorough 160, the
Department of Defense announces the
forthcoming sub committee meeting:

Subcommittees of the Commission
will conduct preparatory work meetings
at Ft. Bragg and Camp Lejeune, North
Carolina June 19th to gather
information, conduct research and
analyze relevant issues and facts in
preparation for a meeting of the
Commission. Pursuant to section 102-
3.160(a) of 41 Code of Federal
Regulations (CFR), these subcommittee
meetings are not open to the public, and
the subcommittees are required to report
their findings to the Commission for
further deliberation.

Dated: May 18, 2007.

L.M. Bynum,
Alternate OSD Federal Register Liaison
Officer, DoD.

[FR Doc. 07-2596 Filed 5-22-07; 10:59 am]

BILLING CODE 5001-06-M

DEPARTMENT OF DEFENSE

Office of the Secretary

Sub Committee Meeting of the President's Commission on Care for America's Returning Wounded Warriors

AGENCY: Department of Defense.

ACTION: Federal Advisory Committee
Sub Committee Meeting Notice.

SUMMARY: Pursuant to the Federal
Advisory Committee Act of 1972 (5
U.S.C., Appendix, as amended), the
Sunshine in the Government Act of
1976 (5 U.S.C. 552b, as amended) and
41 Code of Federal Regulations (CFR)
102-3.140 through 160, the Department
of Defense announces the forthcoming
sub committee meeting:

Subcommittees of the Commission
will conduct preparatory work meetings
in the New Jersey area June 15th to
gather information, conduct research
and analyze relevant issues and facts in
preparation for a meeting of the
Commission. Pursuant to section 102-
3.160(a) of 41 Code of Federal
Regulations (CFR), these subcommittee
meetings are not open to the public, and
the subcommittees are required to report
their findings to the Commission for
further deliberation. Locations include
the East Orange VA Health Center.
Additionally, the Sub Committees may
visit public and private hospitals in the
area for investigation of Centers of
Excellence that apply to the
Commission's Charter.

Dated: May 18, 2007.

L.M. Bynum,
Alternate OSD Federal Register Liaison
Officer, DoD.

[FR Doc. 07-2597 Filed 5-22-07; 8:45 am]

BILLING CODE 5001-06-M

ELECTION ASSISTANCE COMMISSION

Sunshine Act Notice

AGENCY: United States Election
Assistance Commission.

ACTION: Notice of Public Teleconference
Meetings for the Working
Subcommittees of the Technical
Guidelines Development Committee.

DATES AND TIMES: